Physician profile
Mark A Wells
NPI 1932319316
$487.59
in general payments reported to CMS, 2019-2025
11 companies · $33.59 in 2025
The $33.59 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $48.73 · 2021: $128 · 2022: $57.79 · 2023: $28.50 · 2024: $15.99 · 2025: $33.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $252.27 | 2019-2025 | Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.51 | 2019-2020 | |
| Amgen INC. | $41.46 | 2022-2025 | Uplizna |
| Allergan, INC. | $18.64 | 2019 | |
| Gilead Sciences, INC. | $18.08 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Celgene Corporation | $15.99 | 2024 | Zeposia |
| Boston Scientific Corporation | $13.39 | 2023 | Spyglass |
| Merck Sharp & Dohme LLC | $12.35 | 2019 | |
| Ucb, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.